|本期目录/Table of Contents|

[1]袁明利,郑宝琴.血清S100A9、S100A2在NSCLC患者中的变化及预后的意义[J].中华肺部疾病杂志,2021,(06):779-781.[doi:10.3877/cma.j.issn.1674-6902.2021.06.018]
点击复制

血清S100A9、S100A2在NSCLC患者中的变化及预后的意义(PDF)

《中华肺部疾病杂志》[ISSN:1006-6977/CN:61-1281/TN]

卷:
期数:
2021年06期
页码:
779-781
栏目:
临床研究
出版日期:
2021-12-20

文章信息/Info

Title:
-
作者:
袁明利; 郑宝琴
751100 宁夏,宁夏回族自治区吴忠市人民医院医学检验科
Author(s):
-
关键词:
非小细胞肺癌;  S100钙结合蛋白A9;  S100钙结合蛋白A2;  预后
Keywords:
-
分类号:
R734.2
DOI:
10.3877/cma.j.issn.1674-6902.2021.06.018
摘要:
目的 分析血清S100钙结合蛋白A9(S100A9)、S100钙结合蛋白A2(S100A2)在非小细胞肺癌(NSCLC)患者中的变化及预后的意义。方法 选取2019年1月至2020年10月我院收治的46例NSCLC患者为对象,选择同期在我院进行健康体检的32例为对照组。对比两组血清S100A9、S100A2水平。统计NSCLC患者预后,依据预后情况分为生存者和死亡者。Logistic多因素回归分析分析影响NSCLC患者预后的因素。绘制工作特征曲线(ROC),以曲线下面积(AUC)分析血清S100A9、S100A2联合检测对NSCLC患者预后。结果 观察组血清S100A9、S100A2水平均高于对照组(P<0.05)。截止随访结束,病死率为26.08%。Logistic回归分析结果,临床分期为Ⅲ期、分化程度为低分化、血清S100A9及S100A2水平均为影响NSCLC患者预后的危险因素(OR=2.824、2.790、3.401、3.102,P<0.05)。ROC结果显示,血清S100A9、S100A2预测NSCLC患者预后的最佳点分别为302.11 ng/L、7.59 μg/L,两者联合的特异度为97.92%,高于血清S100A9、S100A2, S100A9、S100A2两者联合预测NSCLC患者预后的AUC为0.899,高于S100A9、S100A2单独预测的AUC(P<0.05)。结论 血清S100A9、S100A2两者联合检测对NSCLC患者预后有意义。
Abstract:
-

参考文献/References:

1 钱桂生. 肺癌不同病理类型发病率的变化情况及其原因[J/CD]. 中华肺部疾病杂志(电子版), 2011, 4(1): 1-5.
2 房延凤, 马李杰, 刘雁声, 等. 非小细胞肺癌E19-Del、L858R突变临床特征分析[J/CD]. 中华肺部疾病杂志(电子版), 2020, 13(2): 164-168.
3 Jonna S, Subramaniam DS. Molecular diagnostics and targeted therapies in non-small cell lung cancer(NSCLC): an update[J]. Discov Med, 2019, 27(148): 167-170.
4 Liao WC, Huang BS, Yu YH, et al. Galectin-3 and S100A9: Novel diabetogenic factors mediating pancreatic cancer-associated diabetes[J]. Diabetes Care, 2019, 42(9): 1752-1759.
5 Li C, Chen Q, Zhou Y, et al. S100A2 promotes glycolysis and proliferation via GLUT1 regulation in colorectal cancer[J]. FASEB J, 2020, 34(10): 13333-13344.
6 Sun J, Ambrus JI, Russell CC, et al. Targeting the S100A2-p53 interaction with a series of 3,5-bis(trifluoromethyl)benzene sulfonamides: synthesis and cytotoxicity[J]. Chem Med Chem, 2021, 16(18): 2851-2863.
7 王书航, 王 洁. 2018年V3版NCCN非小细胞肺癌指南更新要点解读[J]. 华西医学, 2018, 33(4): 388-392.
8 Arbour KC, Riely GJ. Systemic therapy for locally advanced and metastatic non-small cell lung cancer: a review[J]. JAMA, 2019, 322(8): 764-774.
9 郭涛弦, 范红松, 罗 勤. 非小细胞肺癌患者血清S100A8, S100A9, MMP-9的表达及意义[J]. 国际呼吸杂志, 2020, 40(22): 1729-1734.
10 Pennell NA, Arcila ME, Gandara DR, et al. Biomarker testing for patients with advanced non-small cell lung cancer: real-world issues and tough choices[J]. Am Soc Clin Oncol Educ Book, 2019, 39(25): 531-542.
11 Tan AC. Targeting the PI3K/Akt/mTOR pathway in non-small cell lung cancer(NSCLC)[J]. Thorac Cancer, 2020, 11(3): 511-518.
12 She C, Wang R, Lu C, et al. Prognostic factors and outcome of surgically treated patients with brain metastases of non-small cell lung cancer[J]. Thorac Cancer, 2019, 10(2): 137-142.
13 Hu ZG, Hu K, Li WX, et al. Prognostic factors and nomogram for cancer-specific death in non small cell lung cancer with malignant pericardial effusion[J]. PLoS One, 2019, 14(5): 72-75.
14 Endo M, Shiono S, Suzuki K, et al. Long-term outcome of pulmonary segmentectomy for lung cancer[J]. Kyobu Geka, 2019, 72(7): 543-549.
15 Zha H, Li X, Sun H, et al. S100A9 promotes the proliferation and migration of cervical cancer cells by inducing epithelial mesenchymal transition and activating the Wnt/β catenin pathway[J]. Int J Oncol, 2019, 55(1): 35-44.
16 Wang H, Hu X, Yang F, et al. miR-325-3p promotes the proliferation, invasion, and EMT of breast cancer cells by directly targeting S100A2[J]. Oncol Res, 2021, 28(7): 731-744.
17 Zhao Z, Zhang C, Zhao Q. S100A9 as a novel diagnostic and prognostic biomarker in human gastric cancer[J]. Scand J Gastroenterol, 2020, 55(3): 338-346.
18 寇晓桂, 陈葆青. S100A2检测在非小细胞肺癌并发胸腔积液诊断中的价值[J]. 陕西医学杂志, 2018, 47(6): 745-747.

备注/Memo

备注/Memo:
通信作者: 袁明利,Email: 913592864@qq.com
更新日期/Last Update: 2021-12-20